Researcher.Life Logo

JAC-Antimicrobial Resistance : Impact Factor & More

eISSN: 2632-1823pISSN: 2632-1823
JournalOpen Access

Key Metrics

Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on JAC-Antimicrobial Resistance

JAC-Antimicrobial Resistance Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher OXFORD UNIV PRESS
Language English
Frequency Quarterly
Article Processing ChargesGBP 1794
Publication Time16
Editorial Review ProcessPeer review
General Details
LanguageEnglish
Society/Institute/SponsorBritish Society for Antimicrobial Chemotherapy
FrequencyQuarterly
Publication Start Year2019
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessPeer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in JAC-Antimicrobial Resistance ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in JAC-Antimicrobial Resistance

Clinical effectiveness and pharmacoeconomic impact of long-acting lipoglycopeptides in a multicenter outpatient day hospital model: a real-world Italian study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with gram-negative bacterial bloodstream infections: a retrospective cohort study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Extended-spectrum beta-lactamase producing pathogens as key drivers of recurrent urinary tract infections and rejection after kidney transplantation: a five-year single-centre study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
DoxyPEP in clinical practice: selective use among high-risk MSM on Prep
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Immuno-modulation of innate and adaptive immune response in patients with sepsis
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Burden of advanced HIV disease among inpatients at the clinical services department of MRC unit the Gambia: a retrospective cohort study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Clinical effectiveness and pharmacoeconomic impact of long-acting lipoglycopeptides in a multicenter outpatient day hospital model: a real-world Italian study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with gram-negative bacterial bloodstream infections: a retrospective cohort study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Extended-spectrum beta-lactamase producing pathogens as key drivers of recurrent urinary tract infections and rejection after kidney transplantation: a five-year single-centre study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
DoxyPEP in clinical practice: selective use among high-risk MSM on Prep
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Immuno-modulation of innate and adaptive immune response in patients with sepsis
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance
Burden of advanced HIV disease among inpatients at the clinical services department of MRC unit the Gambia: a retrospective cohort study
  • 22 Apr 2026
  • JAC-Antimicrobial Resistance

FAQs on JAC-Antimicrobial Resistance